Status:
COMPLETED
Evaluation of Patients Treated With HMG-CoA Reductase Inhibitors to Reach Cholesterol Target Values
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolaemia
Eligibility:
All Genders
18+ years
Brief Summary
This study is non-interventional study of patients who are treated with any HMGCoA reductase inhibitors (rosuvastatin, simvastatin,atorvastatin and fluvastatin) available in Bosnia and Herzegovina for...
Detailed Description
Non-interventional study to assess reaching of cholesterol target values in patients treated with HMG-CoA reductase inhibitors in Bosnia and Herzegovina
Eligibility Criteria
Inclusion
- Patients, treated with one HMG-CoA reductase inhibitors for at least 6 months without changing the dose for the last 4 weeks at least
- All patients must sign informed consent form
Exclusion
- Patients who have not signed the Informed Consent Form
- Patients with contraindication for the treatment with HMG-CoA reductase inhibitors as per SmPC approved in Bosnia and Herzegovina
Key Trial Info
Start Date :
April 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT01483950
Start Date
April 1 2012
End Date
January 1 2013
Last Update
February 5 2013
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Banja Luka, Bosnia and Herzegovina
2
Research Site
Bijeljina, Bosnia and Herzegovina
3
Research Site
Doboj, Bosnia and Herzegovina
4
Reserach Site
Gradiška, Bosnia and Herzegovina